Patents by Inventor Wayne I. Lencer
Wayne I. Lencer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240042042Abstract: Provided herein, in some aspects, are delivery vehicles comprising a ceramide and an agent to be delivered attached to the ceramide. In some embodiments, the ceramide does not comprise a fatty acid (i.e., is a sphingosine). In some embodiments, the ceramide comprises a fatty acid. In some embodiments, the ceramide is a glycoceramide. In some embodiments, the agent is attached to the ceramide covalently (e.g., via a linker). In some embodiments, the agent to be delivered is a therapeutic agent. The ceramide is able to deliver the agent to a cell or to a cellular compartment, as well as across the musical barrier. In some embodiments, agents delivered using the ceramide described herein exhibit longer half-life, compared to agents delivered alone. Methods of delivering a therapeutic agent to a subject for treating a disease using the ceramide delivery vehicle are also provided.Type: ApplicationFiled: August 11, 2023Publication date: February 8, 2024Applicant: Children's Medical Center CorporationInventors: Wayne I. Lencer, Daniel JF Chinnapen, Richard I. Duclos
-
Patent number: 11771771Abstract: Provided herein, in some aspects, are delivery vehicles comprising a ceramide and an agent to be delivered attached to the ceramide. In some embodiments, the ceramide does not comprise a fatty acid (i.e., is a sphingosine). In some embodiments, the ceramide comprises a fatty acid. In some embodiments, the ceramide is a glycoceramide. In some embodiments, the agent is attached to the ceramide covalently (e.g., via a linker). In some embodiments, the agent to be delivered is a therapeutic agent. The ceramide is able to deliver the agent to a cell or to a cellular compartment, as well as across the musical barrier. In some embodiments, agents delivered using the ceramide described herein exhibit longer half-life, compared to agents delivered alone. Methods of delivering a therapeutic agent to a subject for treating a disease using the ceramide delivery vehicle are also provided.Type: GrantFiled: April 12, 2019Date of Patent: October 3, 2023Assignee: Children's Medical Center CorporationInventors: Wayne I. Lencer, Daniel J F Chinnapen, Richard I. Duclos
-
Publication number: 20230132279Abstract: Provided herein, in some aspects, are delivery vehicles comprising a glycosphingolipid and an agent to be delivered attached to the glycosphingolipid. In some embodiments, the glycosphingolipid comprises an oligosaccharide and a short chain (e.g., C0-C3) ceramide. In some embodiments, the agent to be delivered is a therapeutic agent. The glycosphingolipid is able to deliver the agent to a cell or to a cellular compartment, as well as across the musical barrier. In some embodiments, agents delivered using the glycosphingolipid described herein exhibit longer half-life, compared to agents delivered alone. Methods of delivering a therapeutic agent to a subject for treating a disease using the glycosphingolipid delivery vehicle are also provided.Type: ApplicationFiled: December 22, 2022Publication date: April 27, 2023Applicant: Children's Medical Center CorporationInventors: Wayne I. Lencer, Daniel JF Chinnapen
-
Patent number: 11559568Abstract: Provided herein, in some aspects, are delivery vehicles comprising a glycosphingolipid and an agent to be delivered attached to the glycosphingolipid. In some embodiments, the glycosphingolipid comprises an oligosaccharide and a short chain (e.g., C0-C3) ceramide. In some embodiments, the agent to be delivered is a therapeutic agent. The glycosphingolipid is able to deliver the agent to a cell or to a cellular compartment, as well as across the musical barrier. In some embodiments, agents delivered using the glycosphingolipid described herein exhibit longer half-life, compared to agents delivered alone. Methods of delivering a therapeutic agent to a subject for treating a disease using the glycosphingolipid delivery vehicle are also provided.Type: GrantFiled: October 26, 2018Date of Patent: January 24, 2023Assignee: Children's Medical Center CorporationInventors: Wayne I. Lencer, Daniel J F Chinnapen
-
Publication number: 20210338823Abstract: Provided herein, in some aspects, are delivery vehicles comprising a ceramide and an agent to be delivered attached to the ceramide. In some embodiments, the ceramide does not comprise a fatty acid (i.e., is a sphingosine). In some embodiments, the ceramide comprises a fatty acid. In some embodiments, the ceramide is a glycoceramide. In some embodiments, the agent is attached to the ceramide covalently (e.g., via a linker). In some embodiments, the agent to be delivered is a therapeutic agent. The ceramide is able to deliver the agent to a cell or to a cellular compartment, as well as across the musical barrier. In some embodiments, agents delivered using the ceramide described herein exhibit longer half-life, compared to agents delivered alone. Methods of delivering a therapeutic agent to a subject for treating a disease using the ceramide delivery vehicle are also provided.Type: ApplicationFiled: April 12, 2019Publication date: November 4, 2021Applicant: Children's Medical Center CorporationInventors: Wayne I. Lencer, Daniel JF Chinnapen, Richard I. Duclos
-
Publication number: 20210030880Abstract: Provided herein, in some aspects, are delivery vehicles comprising a ceramide and an agent to be delivered attached to the ceramide. In some embodiments, the ceramide does not comprise a fatty acid (i.e., is a sphingosine). In some embodiments, the ceramide comprises a fatty acid. In some embodiments, the ceramide is a glycoceramide. In some embodiments, the agent is attached to the ceramide covalently (e.g., via a linker). In some embodiments, the agent to be delivered is a therapeutic agent. The ceramide is able to deliver the agent to a cell or to a cellular compartment, as well as across the musical barrier. In some embodiments, agents delivered using the ceramide described herein exhibit longer half-life, compared to agents delivered alone. Methods of delivering a therapeutic agent to a subject for treating a disease using the ceramide delivery vehicle are also provided.Type: ApplicationFiled: April 12, 2019Publication date: February 4, 2021Applicant: Children's Medical Center CorporationInventors: Wayne I. Lencer, Daniel JF Chinnapen
-
Patent number: 10806793Abstract: Described herein are compositions and methods useful for allowing for the absorption (passage) of agents of interest, such as therapeutic agents, across epithelial and mucosal barriers and/or into certain subcellular compartments of the cell, such as the recycling endosome (RE), Golgi, and the endoplasmic reticulum (ER).Type: GrantFiled: November 20, 2017Date of Patent: October 20, 2020Assignee: Children's Medical Center CorporationInventors: Wayne I. Lencer, Daniel J F Chinnapen, Randy Mrsny
-
Publication number: 20200289619Abstract: Provided herein, in some aspects, are delivery vehicles comprising a glycosphingolipid and an agent to be delivered attached to the glycosphingolipid. In some embodiments, the glycosphingolipid comprises an oligosaccharide and a short chain (e.g., C0-C3) ceramide. In some embodiments, the agent to be delivered is a therapeutic agent. The glycosphingolipid is able to deliver the agent to a cell or to a cellular compartment, as well as across the musical barrier. In some embodiments, agents delivered using the glycosphingolipid described herein exhibit longer half-life, compared to agents delivered alone. Methods of delivering a therapeutic agent to a subject for treating a disease using the glycosphingolipid delivery vehicle are also provided.Type: ApplicationFiled: October 26, 2018Publication date: September 17, 2020Applicant: Children's Medical Center CorporationInventors: Wayne I. Lencer, Daniel JF Chinnapen
-
Patent number: 10765757Abstract: Described herein are compositions and methods useful for allowing for the absorption (passage) of agents of interest, such as therapeutic agents, across epithelial and mucosal barriers and/or into certain subcellular compartments of the cell, such as the recycling endosome (RE), Golgi, and the endoplasmic reticulum (ER).Type: GrantFiled: September 2, 2016Date of Patent: September 8, 2020Assignee: Children's Medical Center CorporationInventors: Wayne I. Lencer, Daniel J F Chinnapen, Randy Mrsny
-
Publication number: 20180333499Abstract: Described herein are compositions and methods useful for allowing for the absorption (passage) of agents of interest, such as therapeutic agents, across epithelial and mucosal barriers and/or into certain subcellular compartments of the cell, such as the recycling endosome (RE), Golgi, and the endoplasmic reticulum (ER).Type: ApplicationFiled: November 20, 2017Publication date: November 22, 2018Inventors: WAYNE I. LENCER, DANIEL JF CHINNAPEN, RANDY MRSNY
-
Publication number: 20180133332Abstract: Described herein are compositions and methods useful for allowing for the absorption (passage) of agents of interest, such as therapeutic agents, across epithelial and mucosal barriers and/or into certain subcellular compartments of the cell, such as the recycling endosome (RE), Golgi, and the endoplasmic reticulum (ER).Type: ApplicationFiled: November 20, 2017Publication date: May 17, 2018Inventors: WAYNE I. LENCER, DANIEL JF CHINNAPEN, RANDY MRSNY
-
Publication number: 20170095563Abstract: Described herein are compositions and methods useful for allowing for the absorption (passage) of agents of interest, such as therapeutic agents, across epithelial and mucosal barriers and/or into certain subcellular compartments of the cell, such as the recycling endosome (RE), Golgi, and the endoplasmic reticulum (ER).Type: ApplicationFiled: September 2, 2016Publication date: April 6, 2017Applicant: Children's Medical Center CorporationInventors: Wayne I. Lencer, Daniel JF Chinnapen, Randy Mrsny
-
Patent number: 9457097Abstract: Described herein are compositions and methods useful for allowing for the absorption (passage) of agents of interest, such as therapeutic agents, across epithelial and mucosal barriers and/or into certain subcellular compartments of the cell, such as the recycling endosome (RE), Golgi, and the endoplasmic reticulum (ER).Type: GrantFiled: September 4, 2009Date of Patent: October 4, 2016Assignee: Children's Medical CorporationInventors: Wayne I. Lencer, Daniel J F Chinnapen, Randy Mrsny
-
Patent number: 9072728Abstract: This invention relates to methods and materials involved in the treatment of diseases with severe distal colitis component, and more specifically non-fungal and/or non-microbial induced mucositis of the distal intestinal tract. Kits and pharmaceutical compositions for medical treatments also are provided.Type: GrantFiled: September 20, 2004Date of Patent: July 7, 2015Assignee: Children's Medical Center CorporationInventors: Paul Rufo, Wayne I. Lencer
-
Publication number: 20130045236Abstract: The present disclosure is based in part on the finding that sFc?RI is a novel biomarker for IgE-mediated disorders. Methods for diagnosing, treating and/or monitoring IgE-mediated disorders are also described. The disclosure further provides assays to detect sFc?RI in a sample.Type: ApplicationFiled: September 17, 2010Publication date: February 21, 2013Inventors: Elisabeth-Edda Fiebiger, Wayne I. Lencer
-
Publication number: 20120252727Abstract: Described herein are compositions and methods useful for allowing for the absorption (passage) of agents of interest, such as therapeutic agents, across epithelial and mucosal barriers and/or into certain subcellular compartments of the cell, such as the recycling endosome (RE), Golgi, and the endoplasmic reticulum (ER).Type: ApplicationFiled: September 4, 2009Publication date: October 4, 2012Applicant: Children's Medical Center CorporationInventors: Wayne I. Lencer, Daniel JF Chinnapen, Randy Mrsny
-
Patent number: 7547436Abstract: The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.Type: GrantFiled: February 23, 2006Date of Patent: June 16, 2009Assignees: The Brigham and Women's Hospital, Inc., Brandeis UniversityInventors: Richard S. Blumberg, Wayne I. Lencer, Neil E. Simister
-
Publication number: 20090118343Abstract: This invention relates to methods and materials involved in the treatment of diseases with severe distal colitis component, and more specifically non-fungal and/or non-microbial induced mucositis of the distal intestinal tract. Kits and pharmaceutical compositions for medical treatments also are provided.Type: ApplicationFiled: September 20, 2004Publication date: May 7, 2009Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Paul Rufo, Wayne I. Lencer
-
Patent number: 7067129Abstract: The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.Type: GrantFiled: August 8, 2002Date of Patent: June 27, 2006Assignees: The Brigham and Woman's Hospital, Inc., Brandeis UniversityInventors: Richard S. Blumberg, Neil E. Simister, Wayne I. Lencer
-
Patent number: 7060274Abstract: The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.Type: GrantFiled: August 8, 2002Date of Patent: June 13, 2006Assignees: The Brigham and Women's Hospital, Inc., Brandeis UniversityInventors: Richard S. Blumberg, Neil E. Simister, Wayne I. Lencer